THE EFFECTIVENESS OF THE CONFIDENTIAL UNIT EXCLUSION OPTION

被引:32
作者
PETERSEN, LR
LACKRITZ, E
LEWIS, WF
SMITH, DS
HERRERA, G
RAIMONDI, V
ABERLEGRASSE, J
DODD, RY
机构
[1] AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD
[2] STANFORD UNIV,SCH MED,STANFORD,CA 94305
关键词
D O I
10.1046/j.1537-2995.1994.341095026971.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The confidential unit exclusion (CUE) option is intended to reduce human immunodeficiency virus (HIV) transmission by excluding donors newly infected with HIV who have not yet developed HIV antibody (window-period donors); however, its efficacy in excluding window-period donors has not been evaluated. Study Design and Methods: The use of the CUE option was studied among the donors of 3.7 million units at 18 American Red Cross blood services regions during 1991 and 1992 and among 322 previously HIV-1-seronegative donors who subsequently donated a seropositive unit between 1987 and 1990 at 40 United States blood centers. These seroconverting donors had previously been shown to be highly likely to donate during their window period. Results: On the basis of data from these two populations, it was estimated that only 3 to 5 percent of units donated by window-period donors were not transfused because of the CUE option, that 0.4 percent of all donations were from donors who confidentially excluded their blood from transfusion, and that donors who confidentially excluded their blood were 21 times more likely to be HIV antibody-positive than donors who did not use the CUE option. It is estimated that, if all US blood centers used the CUE option, a total of 2 to 17 otherwise acceptable units donated by window-period donors would not be transfused annually. Conclusion: Although donors who confidentially exclude their blood from transfusion are 21 times more likely to have HIV antibody, the rarity of window-period donors and the infrequency of confidential exclusion by window-period donors cause the CUE option to have minimal impact on transfusion safety.
引用
收藏
页码:865 / 869
页数:5
相关论文
共 19 条
[11]  
PETERSEN LR, 1990, PUBLIC HEALTH REP, V105, P153
[12]   DURATION OF TIME FROM ONSET OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIOUSNESS TO DEVELOPMENT OF DETECTABLE ANTIBODY [J].
PETERSEN, LR ;
SATTEN, GA ;
DODD, R ;
BUSCH, M ;
KLEINMAN, S ;
GRINDON, A ;
LENES, B .
TRANSFUSION, 1994, 34 (04) :283-289
[13]   CONFIDENTIAL UNIT EXCLUSION - HOW SHOULD IT BE EVALUATED [J].
PETERSEN, LR .
TRANSFUSION, 1991, 31 (09) :869-870
[14]  
PETERSEN LR, 1992, 5TH NATL FOR AIDS HE, P25
[15]   COLLECTION AND TRANSFUSION OF BLOOD IN THE UNITED-STATES, 1982-1988 [J].
SURGENOR, DM ;
WALLACE, EL ;
HAO, SHS ;
CHAPMAN, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (23) :1646-1651
[16]   TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) BY BLOOD-TRANSFUSIONS SCREENED AS NEGATIVE FOR HIV ANTIBODY [J].
WARD, JW ;
HOLMBERG, SD ;
ALLEN, JR ;
COHN, DL ;
CRITCHLEY, SE ;
KLEINMAN, SH ;
LENES, BA ;
RAVENHOLT, O ;
DAVIS, JR ;
QUINN, MG ;
JAFFE, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (08) :473-478
[17]  
1986, ADDITIONAL RECOMMEND
[18]  
1992, REIVISED RECOMMENDAT
[19]  
1989, MMWR-MORBID MORTAL W, V38, P2